[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endoscopic-ultrasound-eus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endoscopic-ultrasound-eus":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100641844","eus-guided-gallbladder-drainage-versus-conservative-management-in-patients-unfit-for-surgery-after-a-biliary-event-without-cholecystitis-drecon-study-100641844",false,"NCT07655778","EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study","Multicenter Comparative Clinical Trial: EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study: (DRainage, Endoscopic Ultrasound, CONservative)","DRECON","Inclusion Criteria:\n\n* Patients ≥ 18 years of age\n* Patients who have experienced a benign biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis) and are candidates for elective cholecystectomy\n* Patients deemed unfuit for surgery (age ≥ 80 years, ASA score ≥ 3, Charlson Comorbidity Index ≥ 5) or who voluntarily refuse surgery\n* Diagnosis of lithogenic\u002Flithiasic material in the gallbladder by imaging (biliary sludge, microlithiasis, and\u002For cholelithiasis)\n* Signed informed consent\n\nExclusion Criteria:\n\n* No signed informed consent\n* Prior cholecystectomy\n* Biliary event secondary to malignant etiology\n* Acute cholecystitis diagnosed according to Tokyo 2018 criteria\n* Moderate-to-severe ascites without prior paracentesis\n* Perforated gallbladder\n* Severe coagulopathy (INR \\> 1.5) or thrombocytopenia (platelets \\\u003C 50,000\u002FμL) not correctable\n* Any clinical condition preventing sedation\n* Patient dependent for daily activities (ECOG ≥ 4)","ALL","18 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cholecystectomy is considered the standard definitive treatment after an acute biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis). However, in elderly patients and\u002For those with significant comorbidities, surgery is often not feasible, leaving this population at high risk of biliary event recurrence (approximately 25-31% per year without treatment).\n\nEUS-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent (LAMS) is an established endoscopic technique currently recommended for acute cholecystitis in patients unfit for surgery. It creates an internal fistula between the gallbladder and the adjacent digestive tract, allowing direct endoscopic access for stone clearance (cholecystoscopy). This approach could theoretically prevent biliary event recurrence similarly to cholecystectomy.\n\nThe DRECON study (DRainaige, Endoscopic ultrasound, CONservative) is a multicenter, randomized, comparative clinical trial evaluating whether EUS-GBD with LAMS reduces biliary recurrence at 1 year compared to conservative managment (CM) in patients unfit for surgery after a biliary event without acute cholecystitis who are candidates for elective cholecystectomy.\n\nPrimary hypothesis: EUS-GBD will reduce the risk of biliary event recurrence (biliary colic, acute pancreatitis, cholangitis, choledocholithiasis, or cholecystitis) at 1 year of follow-up compared to conservative management in patients unfit for surgery with gallbladder lithiasis.\n\nEstimated sample: 110 patients (55 per arm). Randomization 1:1 (EUS-GBD vs CM), stratified by centre and prior biliary sphincterotomy. Duration: 24 months recruitment + 12 months follow-up (total 3 years).\n\nParticipating centres: Hospital Universitari Mútua de Terrassa (coordinating centre), Hospital Universitari de Bellvitge, Hospital General de Granollers, Hospital Universitari Parc Taulí de Sabadell, Hospital Universitari de la Santa Creu i Sant Pau, Hospital Clínico Universitario de Valencia, Hospital General Universitario Dr Balmis and Complexo Hospitalario Universitario de A Coruña.",[27,28,29,30,31,32,33,34],"Cholecystectomy","Gallbladder","Endoscopic Ultrasound (EUS)","Cholelithiasis","Acute Pancreatitis Due to Common Bile Duct Calculus","Biliary Colic","Acute Pancreatitis Due to Gallstones","Cholangitis; Choledocholithiasis",[36,37,38,39,40,29],"gallbladder","gallblader drainage","conservative treatment","biliary recurrence","cholecystectomy","NOT_YET_RECRUITING","2026-06-17",{"date":44,"type":45},"2026-06-22","ACTUAL",{"date":47,"type":21},"2026-07-01",{"date":49,"type":21},"2029-07-01",{"name":51,"class":52},"Hospital Mutua de Terrassa","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100622251","an-artificial-intelligence-system-for-multimodal-multi-class-diagnosing-solid-pancreatic-lesions-based-on-endoscopic-ultrasound-100622251","NCT07381192","An Artificial Intelligence System for Multimodal, Multi-class Diagnosing Solid Pancreatic Lesions Based on Endoscopic Ultrasound","Inclusion Criteria:\n\n1. Patients aged ≥18 years scheduled for EUS with suspected solid pancreatic lesions based on clinical symptoms, medical history, laboratory tests or radiological examinations agree to participate in the research and be able to sign informed consent.\n2. Patients with no prior history of treatment for pancreatic lesions.\n\nExclusion Criteria:\n\n1. Patients with absolute contraindications to EUS examination.\n2. Pregnancy or lactating.\n3. Uncorrectable coagulopathy(PTT\\>50 seconds or INR\\>1.5) and\u002For uncorrectable thrombocytopenia(platelet count\\\u003C50×109\u002FL).\n4. Upper gastrointestinal obstruction.\n5. Patients who underwent surgical treatment or anatomical alterations of the pancreas due to lesions in other thoracic and\u002For abdominal organs, as well as patients with congenital anatomical abnormalities.\n6. Patients who have undergone biliary\u002Fpancreatic duct stent placement.\n7. Patients who refuse to sign the informed consent.",true,{"count":61,"type":21},383,"6 Months","OBSERVATIONAL","The aim of this study is to validate an artificial intelligence system named iEUS-SPL(intelligent endoscopic ultrasound system-solid pancreatic lesion) for detecting and multimodal, multi-class diagnosing solid pancreatic lesions during endoscopic ultrasound(EUS) examination.",[29,66],"Solid Pancreatic Lesion",[68,69],"endoscopic ultrasound","solid pancreatic lesion","RECRUITING","2026-01-23",{"date":73,"type":45},"2026-02-02",{"date":75,"type":45},"2025-09-01",{"date":77,"type":21},"2028-06-30",{"name":79,"class":52},"Qilu Hospital of Shandong University",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":80},"100613868","endoscopic-ultrasound-guided-radiofrequency-ablation-for-upper-gastrointestinal-tract-lesions-100613868","NCT07272187","Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions","Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions - a Prospective Study","EURAGIL","Inclusion Criteria:\n\n* Patients with one or more lesions amendable to undergo EUS-RFA\n\n  * Insulinomas ≤ 25 mm confirmed by a 72-h fasting test, cross-sectional scanning, and a biopsy with low Ki67 index (\\\u003C10%)\n  * Non-functional pNEN lesions between 10-20 mm and growing, confirmed by a biopsy with low Ki67 index (\\\u003C10%), or larger pNEN lesions in patients who are not candidates for surgical treatment\n  * Unilateral APA with benign characteristics on non-contrast enhanced CT located in the left adrenal and confirmed lateralization on AVS\n\n    * Adult habile patients\n    * Signed informed consent\n\nExclusion Criteria:\n\n* Severe multimorbidity (ASA score ≥ IV or ECOG performance score ≥ 4)\n\n  * Uncorrected coagulopathy (INR \\>1.8 or thrombocyte count \\\u003C 50 mia\u002FL)\n  * Pregnancy\n  * Metastatic malignancy with expected remaining life expectancy \\\u003C 3 years\n  * Stenosis in upper GI tract or altered anatomy (e.g. previous gastrectomy) preventing the passage of an echoendoscope",{"count":90,"type":21},138,"The goal of this observational study is to evaluate the long-term clinical effectiveness of EUS-RFA and quality of life in patients with pancreatic or adrenal tumors recieving EUS-RFA.\n\nPrimary Objectives:\n\n* Clinical effectiveness: To evaluate the proportion of included patients who show doc-umented improvement in their clinical symptoms and biochemical parameters (blood test results) over time.\n* Patient satisfaction: To assess patient satisfaction with the procedure and subsequent disease-related quality of life, measured using validated questionnaires.\n\nSecondary Objectives:\n\n* Safety: To determine the proportion of treated patients who experience complications, as defined by the AGREE classification, within 30 days after the procedure.\n* Technical success: To assess the proportion of included patients in whom the EUS-RFA procedure can be successfully completed.\n\nExploratory Objectives:\n\n• To identify factors associated with adverse events and factors related to clinical success or lack there of.\n\nThe study is observational. All participant will receive EUS-RFA as part of their standard clinical care.\n\nParticipants will:\n\n* Undergo EUS-RFA, in which a fine needle is guided into the tumor using an endo-scope and ultrasound imaging. Radiofrequency energy is applied through the needle to heat and destroy tumor cells while protecting the surrounding tissue.\n* Have follow-up visits including blood tests, imaging scans, and clinical evaluations at regular intervals for up to 5 years after treatment.\n* Complete validated questionnaires about satisfaction and quality of life.\n\nThe study will include approximately 138 patients recruited between 2025 and 2035 from two Danish hospital departments (Herlev and Gentofte Hospital and Rigshospitalet). Data collection will continue until 2040 to assess long-term outcomes.\n\nThis study may help determine whether EUS-RFA can serve as a safe and effective alternative to traditional surgery for selected patients with small hormone-producing or benign tumors in the pancreas or adrenal glands, potentially reducing surgical risks and improving recovery and quality of life.",[93,94,95,96,29,97],"Insulinoma; Pancreas","MEN1","NETs","Radiofrequency Ablation","Conn Syndrome","2025-11-26",{"date":100,"type":45},"2025-12-09",{"date":102,"type":45},"2025-11-01",{"date":104,"type":21},"2041-12-31",{"name":106,"class":52},"Herlev Hospital"]